FindaCure
liked
Bitcoin is a volatile asset.
We first recommended Bitcoin to Fundstrat clients in 2017 (1%-2% allocation)
- Bitcoin 2017 ~$1,000
Since then (past 8.5 years), $Bitcoin (BTC.CC)$:
- 6 declines > -50%
- 3 declines > - 75%
2025, Bitcoin 100x from our first recommendation
TAKEAWAY:
To have gained from that 100x Supercycle, one had to stomach existential moments to HODL
WHY?
Crypto prices are discounting a massive future. So doubts create volatility
TODAY:
We believe $ETH is embarking o...
We first recommended Bitcoin to Fundstrat clients in 2017 (1%-2% allocation)
- Bitcoin 2017 ~$1,000
Since then (past 8.5 years), $Bitcoin (BTC.CC)$:
- 6 declines > -50%
- 3 declines > - 75%
2025, Bitcoin 100x from our first recommendation
TAKEAWAY:
To have gained from that 100x Supercycle, one had to stomach existential moments to HODL
WHY?
Crypto prices are discounting a massive future. So doubts create volatility
TODAY:
We believe $ETH is embarking o...
4
FindaCure
liked
$TeraWulf (WULF.US)$
Looking ahead, TeraWulf provided forward-looking guidance, highlighting several key metrics and strategic advancements. The company secured a 10-year agreement for 360 megawatts of IT load, expected to yield approximately $670 million in average annual revenue and over $565 million in net operating income. Despite a net loss of $455 million, non-GAAP adjusted EBITDA improved by 25% to $18.1 million. TeraWulf also increased its annual target for new HPC...
Looking ahead, TeraWulf provided forward-looking guidance, highlighting several key metrics and strategic advancements. The company secured a 10-year agreement for 360 megawatts of IT load, expected to yield approximately $670 million in average annual revenue and over $565 million in net operating income. Despite a net loss of $455 million, non-GAAP adjusted EBITDA improved by 25% to $18.1 million. TeraWulf also increased its annual target for new HPC...
1
FindaCure
liked
$Moleculin Biotech (MBRX.US)$ Moleculin Reports 60% of First 45 Subjects in Pivotal "MIRACLE" Phase 3 AML Trial Consented
GlobeNewswire
2m
Completion of treatment for the first 45 patients on pace for Q1 2026 with initial unblinded data thereafter; blinded response activity tracking within expected range
HOUSTON, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), today provided an enrollment update with 60% of the target number of subj...
GlobeNewswire
2m
Completion of treatment for the first 45 patients on pace for Q1 2026 with initial unblinded data thereafter; blinded response activity tracking within expected range
HOUSTON, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), today provided an enrollment update with 60% of the target number of subj...
2
FindaCure
reacted to and commented on
To me, the weakness in crypto has the all the signs
- of a market maker (or two) with a major “hole” in their balance sheet
Sharks circling to trigger a liquidation / dumping of prices $Bitcoin (BTC.CC)$
Is this pain short-term? Yes
Does this change the $Ethereum (ETH.CC)$ supercycle of Wall Street building on blockchain? No
PS: this is not a time to use leverage. Don’t get liquidated
- of a market maker (or two) with a major “hole” in their balance sheet
Sharks circling to trigger a liquidation / dumping of prices $Bitcoin (BTC.CC)$
Is this pain short-term? Yes
Does this change the $Ethereum (ETH.CC)$ supercycle of Wall Street building on blockchain? No
PS: this is not a time to use leverage. Don’t get liquidated
16
6
$Hyperscale Data (GPUS.US)$ Traders learnt the lessons, News/announcement/letters from GPUS won't be given too much weight. The trick to attract traders by announcing they will make a super tasty cake, but it will take 20, 30, 40 months, etc, is not working anymore. Let the data speaks!
$Hyperscale Data (GPUS.US)$
Nov 25, 2024 Combination 35 -> 1
Jan 17, 2024 Combination 25 -> 1
May 18, 2023 Combination 300 -> 1
Aug 6, 2019 Combination 40 -> 1
Mar 15, 2019 Combination 20 -> 1
LAS VEGAS, March 05, 2025 (GLOBE NEWSWIRE) -- Hyperscale Data, Inc. (NYSE American: GPUS), a diversified holding company (“Hyperscale Data” or the “Company”), today announced that on March 4, 2025, the NYSE Ameri...
Nov 25, 2024 Combination 35 -> 1
Jan 17, 2024 Combination 25 -> 1
May 18, 2023 Combination 300 -> 1
Aug 6, 2019 Combination 40 -> 1
Mar 15, 2019 Combination 20 -> 1
LAS VEGAS, March 05, 2025 (GLOBE NEWSWIRE) -- Hyperscale Data, Inc. (NYSE American: GPUS), a diversified holding company (“Hyperscale Data” or the “Company”), today announced that on March 4, 2025, the NYSE Ameri...
$Modular Medical (MODD.US)$ It is growing at a annual growth rate of 10.9%. The market is driven by factors such as the rising prevalence of diabetes and the increasing demand for user-friendly, affordable, miniature diabetes management devices, such as the MODD new product.
1
FindaCure
commented on
$Modular Medical (MODD.US)$ from the report they had financial issues..but whats interesting is that yesterday they already gain some cash from selling of the common stock around 6mil..i think tht shows the potential..what are your thoughts?
10k report does show a big concern over the cash flow
10k report does show a big concern over the cash flow
2
![[empty]](https://static.moomoo.com/node_futunn_nnq/assets/images/folder.5c37692712.png)
![[error]](https://static.moomoo.com/node_futunn_nnq/assets/images/no-network.991ae8055c.png)